Denali Therapeutics Inc. reports results for the quarter ended September 30 - Earnings Summary

• Denali Therapeutics Inc. reported a quarterly adjusted loss of 66 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -74 cents. The mean expectation of nineteen analysts for the quarter was for a loss of 53 cents per share. Wall Street expected results to range from -88 cents to 29 cents per share.

• Revenue was $17.78 million​; analysts expected $10.66 million.

• Denali Therapeutics Inc.'s reported EPS for the quarter was 37 cents​.

• The company reported quarterly net income of $70.13 million.

• Denali Therapeutics Inc. shares had fallen by 8.8% this quarter and gained 14.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 15.5% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Denali Therapeutics Inc. is $35.00, about 46.1% above its last closing price of $18.86

This summary was machine generated from LSEG data November 3 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)